A tier · strong
The Intergroup Exemestane Study and the MAP.3 prevention trial provide solid randomised efficacy and safety data, though the evidence base is smaller than tamoxifen's and confined to postmenopausal breast cancer populations.
exemestane
Exemestane is a steroidal, irreversible aromatase inactivator approved for postmenopausal hormone receptor-positive breast cancer after tamoxifen and for advanced disease, with additional randomised prevention data from MAP.3. Its adverse profile in trials is dominated by arthralgia, bone loss and fractures, consistent with its class.
the explanation
Exemestane permanently disables the enzyme that makes estrogen, so estrogen levels stay low until the body builds new enzyme. It is an approved breast cancer drug, and the main documented downsides are joint pain, bone thinning and fractures.
regulatory status
Approved prescription medicine
FDA-approved in October 1999 for adjuvant treatment of postmenopausal women with estrogen receptor-positive early breast cancer following two to three years of tamoxifen, and for advanced breast cancer progressing after tamoxifen. Not approved for breast cancer prevention in the US despite MAP.3 data, and not approved for use in men or as an estrogen-control adjunct.
how it works · proposed mechanism
Exemestane is processed by aromatase into a reactive species that permanently inactivates the enzyme.
Suicide substrate inactivation
Exemestane mimics the natural androgen substrate and is accepted into the aromatase active site. Enzymatic processing generates an intermediate that binds covalently, destroying catalytic function.
Recovery requires new enzyme
Because inactivation is irreversible, estrogen suppression persists well beyond drug clearance. Aromatase activity returns only as the tissue synthesises replacement enzyme.
Steroidal backbone effects
Unlike the triazole inhibitors, exemestane retains an androstenedione-derived steroid skeleton with weak intrinsic androgenic character. This contributes to a distinct lipid signature, notably HDL cholesterol reduction without change in LDL.
what’s reported
evidence shape
24 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Exemestane's randomised evidence comes from postmenopausal women with breast cancer or at elevated breast cancer risk, where an absolute reduction in cancer events justifies accepting a documented arthralgia, bone loss and fracture burden under clinical supervision. That justification is entirely absent when the drug is used off-label to control estrogen alongside anabolic steroids: there are no trials in that setting, the irreversible mechanism means over-suppression cannot be quickly reversed by stopping the drug, and profound estradiol deficiency in men is itself a recognised cause of skeletal and metabolic harm.
key published findings
- Human trial (MAP.3, NEJM 2011, n=4,560 postmenopausal women at elevated risk, median follow-up 3 years): exemestane reduced invasive breast cancer by 65% relative to placebo (P=0.002), with annual incidence 0.19% versus 0.55%, and a 73% relative reduction for estrogen receptor-positive tumours.
- Human trial (MAP.3 safety): any adverse event was reported by 88% on exemestane versus 85% on placebo, with bodily pain the notable difference at 46% versus 41% (P<0.001); the investigators reported no excess of fractures, self-reported osteoporosis, cardiovascular toxicity or second cancers over three years.
- Regulatory data (Aromasin US label, Intergroup Exemestane Study versus tamoxifen): arthralgia 15% vs 9%, clinical fractures 4.2% vs 3.1%, osteoporosis 4.6% vs 2.8%, and hot flushes 21% vs 20%.
- Regulatory data (Aromasin US label): plasma HDL cholesterol fell 6-9% in exemestane-treated patients while total cholesterol, LDL cholesterol and triglycerides were unchanged, a lipid signature distinct from the non-steroidal aromatase inhibitors.
- Pharmacology (Aromasin US label): exemestane has a mean terminal half-life of about 24 hours, yet suppresses estrogen for far longer because inactivation of aromatase is covalent and irreversible.
limitations of the evidence
- The randomised base is smaller than tamoxifen's or anastrozole's and is limited to postmenopausal women with or at risk of breast cancer.
- MAP.3's three-year median follow-up is short for characterising cumulative skeletal effects, and exemestane is not FDA-approved for prevention.
- No randomised data exist for use in men, in younger populations, or for any endocrine ancillary purpose.
documented safety signals
- Bone mineral density loss and osteoporosis: 4.6% versus 2.8% for tamoxifen in the Intergroup Exemestane Study.
- Increased clinical fractures: 4.2% versus 3.1% for tamoxifen.
- Arthralgia and musculoskeletal pain: 15% versus 9% for tamoxifen; MAP.3 also showed excess bodily pain (46% vs 41%).
- Adverse lipid effect on HDL cholesterol, reduced 6-9% from baseline, in a direction generally regarded as unfavourable for cardiovascular risk.
- Hot flushes, fatigue, insomnia, headache, dizziness and depression reported commonly.
- Hepatic enzyme and alkaline phosphatase elevations; hepatitis reported rarely.
- Weak androgenic character from the steroidal backbone, with reports of acne, hirsutism and voice changes at higher exposures, distinguishing it from the triazole inhibitors.
- Nausea, fatigue and increased sweating; peripheral oedema and hypertension reported.
- Embryo-fetal toxicity; contraindicated in pregnancy.
- Because inactivation of aromatase is irreversible, excessive estrogen suppression does not resolve promptly on stopping the drug and requires new enzyme synthesis, which removes a margin of correction available with reversible inhibitors.
identity
| full name | Exemestane |
| category | Ancillary & Endocrine |
| modality | small molecule |
| formula | C20H24O2 |
| molar mass | 296.41 g/mol |
| cas | 107868-30-4 |
| half-life | Approximately 24 hours (terminal) |
laboratory handling
| storage | Sugar-coated tablets stored at controlled room temperature, approximately 25 degrees C, with excursions permitted to 15-30 degrees C, in the manufacturer's container. |
| solubility | White to off-white crystalline powder, practically insoluble in water and freely soluble in dimethylformamide, methanol and ethanol; reported melting point around 155 degrees C. |
| co-studied with | Discussed off-label as a longer-acting alternative to reversible aromatase inhibitors, but the irreversible mechanism that appeals in that framing is also what makes accidental over-suppression harder to correct; no randomised evidence exists in this setting. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedUS prescribing information · 2024 · official
ChemicalBook · 2024 · official
The ASCO Post · 2011 · review
New England Journal of Medicine · 2004 · randomized
New England Journal of Medicine · 2011 · randomized
Journal of Clinical Oncology · 2017 · randomized
others in Ancillary & Endocrine